Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure.
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. Cancer Research 2009, 69: 2037-2037. DOI: 10.1158/0008-5472.sabcs-09-2037.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHER2-positive breast cancerResponse groupPre-surgery samplesPathological complete responseBreast cancer patientsRandomized clinical trialsPreoperative chemotherapyComplete responsePlasma protein profileResidual diseaseCancer patientsTumor responseClinical trialsBreast cancerTumor markersChemotherapySerum profileBaseline samplesCancer ResPatientsRD groupEvaluation of changesP componentProtein profiles